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Abstract
Background: Immunoactivation is less evident in secondary progressive MS (SPMS) compared to relapsing-remitting
disease. MicroRNA (miRNA) expression is integral to the regulation of gene expression; determining their impact on
immune-related cell functions, especially CD4+ T cells, during disease progression will advance our understanding of
MS pathophysiology. This study aimed to compare miRNA profiles of CD4+ T cells from SPMS patients to healthy
controls (HC) using whole miRNA transcriptome next-generation sequencing (NGS). Total RNA was extracted from CD4
+ T cells and miRNA expression patterns analyzed using Illumina-based small-RNA NGS in 12 SPMS and 12 HC samples.
Results were validated in a further cohort of 12 SPMS and 10 HC by reverse transcription quantitative polymerase chain
reaction (RT-qPCR).
Results: The ten most dysregulated miRNAs identified by NGS were selected for qPCR confirmation; five (miR-21-5p,
miR-26b-5p, miR-29b-3p, miR-142-3p, and miR-155-5p) were confirmed to be down-regulated in SPMS (p < 0.05). SOCS6
is targeted by eight of these ten miRNAs. Consistent with this, SOCS6 expression is up-regulated in SPMS CD4+ T cells
(p < 0.05). This is of particular interest as SOCS6 has previously been shown to act as a negative regulator of T cell
activation.
Conclusions: Ninety-seven percent of miRNA candidates identified by NGS were down-regulated in SPMS. The down-
regulation of miRNAs and increased expression of SOCS6 in SPMS CD4+ T cells may contribute to reduced immune
system activity in progressive MS.
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Background
Multiple sclerosis (MS) is an autoimmune disease char-
acterized by multifocal inflammatory attacks in the CNS
[1]. In the relapsing-remitting (RRMS) stage of the dis-
ease, CD4+ T cells are among the primary infiltrators
moving from the periphery, through the blood-brain
barrier, and into the CNS [2]. These cells then initiate an
immune response that results in localized demyelination
and corresponding symptoms. The later stage of MS,
secondary progressive (SPMS), is characterized by com-
pounding neurodegeneration and increasing disability;
however, the relevance of inflammation is unclear [3].
As key regulators of gene expression, microRNAs (miR-
NAs) may be affecting the immune-related functions of
CD4+ T cells in SPMS and may help to elucidate the ac-
tions of these cells in SPMS.
MiRNAs are short, non-coding RNA molecules
(~22 bp) that regulate gene expression at the posttran-
scriptional stage by targeting the 3′ untranslated region
of target genes. Their small size and stable structure
make them ideal biomarkers. In recent years, miRNA
expression patterns in MS have been the focus of nu-
merous studies, many of which have concentrated on
using miRNAs as biomarkers for diagnosis and progno-
sis [4]. These studies predominantly use easily acquired
(and often highly heterogeneous) samples such as whole
blood, peripheral blood mononuclear cells (PBMCs),
serum, and plasma. Numerous dysregulated miRNAs
have been identified, however which cell types are actu-
ally responsible for differing miRNA profiles, and the
consequences of altered miRNA expression is not clear
in many studies. Furthermore, it is likely that these het-
erogeneous samples are masking the signal of differen-
tially expressed miRNA in specific cell subtypes. To
overcome this, we have focused on CD4+ T cells in this
study on SPMS.
Next-generation sequencing (NGS) allows for stringent
examination of cell-specific miRNA expression profiles
as well as discovery of previously uncharacterized miR-
NAs. Here, we have used small-RNA NGS analysis of
CD4+ T cells from SPMS patients and healthy controls
(HC). The total coverage approach of NGS generates ex-
pression information on all small RNA species including
all known and novel miRNAs, as well as other small
RNA species (isomiRs and snoRNAs)—a clear advantage
over microarray and candidate approach assays. Three
previous studies in MS have used NGS to effectively
identify miRNA expression profiles in the whole blood
[5, 6], serum [6], and PBMCs [7] from RRMS patients.
However, NGS techniques have not been used for spe-
cific cell types or in SPMS samples.
The miRNA expression profile of CD4+ T cells, either
as instigating molecules or by-products of erroneous
molecular mechanisms, will provide insight into the
function of these cells in SPMS. Here, we used NGS to
provide a comprehensive analysis of the miRNA expres-
sion profiles of CD4+ T cells from SPMS patients and




Whole blood was collected at a single study center from
an initial cohort of 12 SPMS patients and 12 HC and a
replication cohort of 12 SPMS and 10 HC. All patients
were diagnosed with SPMS according to the McDonald
criteria [8] and demonstrated EDSS progression without
evidence of relapse in the 24 months prior to collection.
Controls were age (±5 years) and gender matched
(Table 1). The SPMS patient group was free of MS-
specific treatments for a minimum period of 6 months
prior to collection. Samples were collected at the John
Hunter Hospital, and laboratory work was conducted at
the Hunter Medical Research Institute, Newcastle.
Blood sample processing
PBMCs were isolated from 45 mL of heparinized whole
blood by density gradient centrifugation on lymphoprep
(Axis-Shield PoC AS, Norway). CD4+ T cells were
enriched from the PBMCs using EasySep magnetic nega-
tive selection according to the manufacturer’s protocol
(StemCell Technologies, Canada). The purity of the CD4
Table 1 Details of SPMS and healthy control individuals
Next generation sequencing Replication cohort
SPMS HC SPMS HC
Number 12 12 12 10
Female 9 9 8 5
Age in years (mean ± SD) 60.2 ± 8.3 61.3 ± 9.5 61.4.0 ± 6.5 60.1 ± 5.9
EDSS (mean ± SD) 6.9 ± 0.9 NA 5.9 ± 1.0 NA
Active SPMS 3 NA 4 NA
Disease duration in years (mean ± SD) 25.6 ± 11.1 NA 18.3 ± 6.5 NA
Progression duration (mean ± SD) 10.8 ± 8.1 NA 8.9 ± 6.2 NA
EDSS expanded disability status scale, SD standard deviation, NA not applicable
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+ selection was assessed by flow cytometry using a
FITC-conjugated anti-CD4 antibody (anti-human CD4
antibody, clone OTK4, FITC, catalog# 60016FI, StemCell
Technologies, Canada) on a BD FACSCanto II flow cyt-
ometer and then analyzed using FACSDiva software (BD
Biosciences, USA) at the Analytical Biomolecular Re-
search Facility of the University of Newcastle. All sam-
ples met a minimum purity threshold of >90 %.
RNA isolation
Total RNA was isolated from the CD4+ T cells using the
miRNeasy Mini kit (Qiagen, USA) following the manu-
facturer’s instructions. The quality of the RNA was
assessed using the RNA 6000 Nano kit on a 2100 Bioa-
nalyzer (Agilent Technologies, USA); a RNA integrity
number greater than 8 was deemed suitable for sequen-
cing and reverse transcription quantitative polymerase
chain reaction (RT-qPCR). Purity was measured on an
Epoch spectrophotometer (BioTek, USA), and concen-
tration was measured using the high-sensitivity RNA kit
on Qubit 2.0 Fluorometer (Life Technologies, Thermo
Fisher Scientific, USA).
miRNA sequencing and analysis
A cohort of 12 SPMS and 12 HC samples was run
through NGS at the Diamantina Institute, University of
Queensland, Brisbane, Australia. Samples were individu-
ally barcoded and then sequenced in two multiplexed
pools each containing 12 samples. The sequencing li-
braries were prepared from 1-μg total RNA, using the
TruSeq small RNA preparation kit (Illumina, USA) and
sequenced using the 50-bp fragment protocol on the
HiSeq 2500 platform. The sequencing generated four to
nine million reads per sample, more than sufficient for
expression and discovery applications. The sample se-
quencing reads were demultiplexed using the CASAVA
1.8 software package (Illumina, USA). The Illumina
adapter sequences were trimmed from the fastq files
using Trimmomatic [9]. All reads were aligned and
counted against miRBase 21 [10].
RT-qPCR
Mature miRNA TaqMan assays (Applied Biosystems,
Thermo Fisher Scientific, USA) were used to determine
expression of the ten most differentially expressed miR-
NAs in the initial NGS cohort as well as a replication
cohort of 12 SPMS and 10 HC (assay IDs in miRNA nu-
merical order: 000397, 000399, 000407, 000408, 000409,
000413, 002223, 000464, 002623, 000524). The small
RNA RNU44 (ref: 001094) was used as an endogenous
control. RNU44 has previously been demonstrated to be
a stable control in CD4+ T cells [11], and its stability has
been shown in our 47 samples (mean ± standard devi-
ation Ct value of 23.58 ± 0.63). RNU44 was used for
normalization using the ΔCt method. The relative ex-
pression (2−ΔCt) of all samples (24 SPMS and 22 HC)
was calculated.
Statistical analysis
The two-sample Kolmogorov-Smirnov test (K-S test)
was used to test whether differences in expression levels
were statistically significant between the case and con-
trol groups as implemented in R. The K-S test was
chosen (over the F test comparison of means) because of
the non-normality of the expression level distributions
among miRNAs. Our statistical significance threshold
allowing for multiple testing correction was determined
using the False Discovery Rate (FDR) procedure of
Benjamini-Hochberg [12]. Based on the number of
miRNA elements, this threshold was set at 1.2 × 10−4.
We also considered a relaxed (or nominal) significance
threshold of 0.05. In addition to using statistical signifi-
cance thresholds for miRNA selection, we also included
a count threshold of >800 to exclude miRNAs that had
very low expression levels and were unlikely to be repli-
cated with the less-sensitive RT-qPCR. The K-S test was
also used to determine significant differential miRNA
and SOCS6 expression from the RT-qPCR relative ex-
pression data.
Correlation to patient characteristics
The Pearson correlation coefficient was calculated
using RT-qPCR data for MS samples (n = 24) and pa-
tient characteristics: EDSS, age, disease duration, and
progression duration. A correlation coefficient (r value)
>±0.5 was considered strong, ±0.3–0.49 moderate, and
<±0.29 weak.
Gene target prediction
miRSystem integrates seven different target gene predic-
tion algorithms and contains experimentally validated
data on miRNA:mRNA interactions [13]. This integra-
tion system was used to identify genes that may be tar-
geted by more than one of our identified dysregulated
miRNAs.
Analysis of SOCS6 expression
Five hundred nanograms of total RNA was reverse tran-
scribed using high-capacity cDNA reverse transcription
kits (Applied Biosystems, Thermo Fisher Scientific,
USA) in 21 SPMS and 21 HC samples. qPCR was per-
formed using an exon-spanning TaqMan probe for
SOCS6 (ref: Hs00377781_m1). Expression of SOCS6 was
determined as relative expression to the housekeeping
genes GAPDH (ref: 4326317E) and β-actin (ref:
4326215E) using a ViiA 7 (Applied Biosystems, Thermo
Fisher Scientific, USA).
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Results
We used NGS to establish miRNA expression profiles in
CD4+ T cells from a cohort of 12 SPMS and 12 HC
samples. RT-qPCR was then employed to validate differ-
ences in miRNA expression in the NGS cohort as well
as a replication cohort of 12 SPMS and 10 HC samples
(total 24 SPMS and 22 HC).
NGS
We observed three statistically significant miRNAs
(miR-451a, miR-1246, and miR-144-5p) at the FDR-
corrected threshold (Additional file 1: Figure S1), which
probably reflects the modest sample size. These miRNAs
were very lowly expressed (<100 reads per sample), and
we were unable to confirm this dysregulation with RT-
qPCR. We also observed 42 miRNAs at the nominal
significance threshold (97 % of these were down-
regulated). Of these 42 miRNAs, only 10 met our sec-
ondary criteria of having a read count >800: miR-21-5p
(p = 0.031), miR-23a-3p (p = 0.007), miR-26b-5p (p =
0.031), miR-27a-3p (p = 0.031), miR-27b-3p (p = 0.031),
miR-29b-3p (p = 0.007), miR-30e-5p (p = 0.031), miR-
142-3p (p = 0.031), miR-155-5p (p = 0.031), and miR-
221-3p (p = 0.031). Each of these miRNAs was found to
be down-regulated in SPMS as summarized in Fig. 1 and
was forwarded for replication testing in an independent
cohort.
RT-qPCR
To confirm our NGS findings, the top ten most dysregu-
lated miRNAs were selected for further analysis in 24
SPMS and 22 HC samples using RT-qPCR (including
the 12 SPMS and 12 HC samples that underwent NGS
analysis). Of these ten miRNAs, RT-qPCR confirmed
significant down-regulation of miR-21-5p (p = 0.0048),
miR-26b-5p (p = 0.007) miR-29b-3p (p = 0.00001), miR-
142-3p (p = 0.05), and miR-155-5p (p = 0.001) in SPMS
CD4+ T cells (Fig. 2). These five miRNAs were
confirmed in the original NGS cohort, the replication
cohort, and the combined cohort. This provides statisti-
cally significant evidence of replication, indicating that
these five miRNAs are very unlikely to be false positives.
A trend of down-regulation of miRNA in SPMS samples
was still observed across all ten miRNAs.
Comparison of methods
Concordance of differential expression can vary between
quantitation methods [14]. To determine the magnitude
of fold-change in SPMS vs. HC, we compared RT-qPCR
and NGS results and found no change in the degree of
decreased expression between NGS and RT-qPCR
methods in the miRNAs confirmed by RT-qPCR (Fig. 3).
Correlation to patient characteristics
No strong correlations between miRNA expression and
patient characteristics were identified (Table 2). How-
ever, moderate positive correlation between EDSS and
miR-21-5p, miR-26b-5p, and miR-29b-3p was seen. Fur-
ther positive correlation was also found between disease
duration and miR-21-5p and miR-155-5p. All miRNAs
demonstrated weak correlation to patient age and pro-
gression duration.
Correlation of miRNA expression and age of HC has
also been calculated as a reference point for age of pa-
tients. Moderate correlations are in bold text.
Target prediction
miRNA fold-change was <2 for all miRNAs. It is there-
fore unlikely that any one particular miRNA is causing a
significant effect on gene expression alone. It is more
likely to be a combination of multiple miRNAs targeting
a few specific genes. Furthermore, as RT-qPCR is a less-
sensitive methodology than NGS, and the trend of
down-regulation is still observed (though not significant)
in the other miRNAs, all ten miRNAs were cross-
analyzed for potential gene targets. miRSystem was used
Fig. 1 Tukey boxplot demonstrating the ten most significantly dysregulated microRNAs identified using NGS. Data is presented as log10 of the
read count and clearly exhibits the down-regulation of miRNAs in SPMS (purple) compared to HC (gray). Whiskers represent data within 1.5
interquartile range (IQR) of the upper and lower quartile. Data points outside of the 1.5 IQR are represented by black dots. *p < 0.05, **p < 0.01
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to identify genes that have multiple target genes in com-
mon, both in the five confirmed miRNAs and all ten
miRNAs identified by NGS. One gene, bromodomain
and WD repeat domain containing 1 (BRWD1), is tar-
geted by all five confirmed miRNAs. No genes are tar-
geted by all ten miRNAs; however, eight genes are
targeted by eight of the miRNAs (Table 3).
These genes are involved in transmembrane ligand
binding, regulation of actin filaments, or are transcrip-
tion factors. However, only one gene is specifically linked
to immune cell function, SOCS6 (suppressor of cytokine
signaling 6). This gene has previously been reported to
negatively regulate T cell activation by promoting
ubiquitin-dependent proteolysis [15] and was conse-
quently selected for further investigated.
SOCS6 expression
Gene expression analysis using RT-qPCR was conducted
to determine whether SOCS6 is up-regulated in SPMS
CD4+ T cells in direct negative correlation to the
miRNA expression (Fig. 4). Both the preliminary and
validation cohorts were analyzed, and SOCS6 expression
is increased in SPMS compared to HC. Normalization
against GAPDH and β-actin generated the same results
(data for β-actin not shown).
Discussion
This is the first study in MS to utilize NGS for miRNA
expression profiling in the CD4+ T cells of SPMS pa-
tients. We found 42 miRNAs that are dysregulated in
the CD4+ T cells of SPMS patients as compared to con-
trols: 97 % of which were down-regulated. TaqMan as-
says confirmed five of these miRNAs (miR-21-5p, miR-
26b-5p, miR-29b-3p, miR-142-3p, and miR-155-5p) to
be down-regulated in SPMS. Each of these miRNAs (ex-
cluding miR-26b) has been reported on previously in
MS though not necessarily in SPMS or CD4+ T cells.
Lindberg et al. [11] identified seven miRNAs dysregu-
lated in CD4+ T cells from RRMS patients but did not
identify dysregulation in any of the five miRNA in this
study. Thus, down-regulation of these miRNAs may be
exclusive to SPMS.
Here, we report a decrease in miR-155-5p expression
in MS. miR-155-5p has a pro-inflammatory role in MS
and is up-regulated in a number of tissues. Studies of
postmortem brain tissue find a gradient of miR-155-5p
expression that peaks in active lesions [16] and associ-
ated neurovascular units [17] and decreases through
chronic lesions and normal appearing white matter to a
low baseline in healthy control (non-MS) white matter
[17, 18]. This increased expression of miR-155 has been
associated with the suppression of CD47 in active lesions
that creates a permissive environment for myelin phago-
cytosis [16]; focal adhesion and cell-cell complex mole-
cules in the blood-brain barrier, thus increasing
permeability [17] and; AKR1C1 and AKR1C2, essential
for biosynthesis of allopregnanolone (a neuroprotective
steroid) [18].
Interestingly, a study of miR-155 in the EAE mouse
model found that miR-155 expression in CD4+ T cells
Fig. 2 Tukey boxplot of top ten miRNAs expression (relative to RNU44) using RT-qPCR. Significant down-regulation of miR-21-5p, miR-26b-3p,
miR-29b-3p, miR-142-3p, and miR-155-5p in SPMS was confirmed. Whiskers represent data within 1.5 interquartile range (IQR) of the upper and
lower quartile. Data points outside of the 1.5 IQR are represented by black dots. p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3 Comparison of miRNA fold-change between NGS and RT-qPCR.
Magnitude of change is consistent between NGS and RT-qPCR
methods
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increases during EAE and that miR-155−/− mice had an
attenuation of EAE [19]. Specifically, Th17 cells lacking
miR-155-5p are unable to cause EAE [20]. miR-155-5p is
required for normal immune function [21], and together,
these studies confirm that the significant role miR-155-
5p over-expression plays in the inflammatory process of
MS. In contrast, our finding of miR-155-5p down-
regulation may be exclusive to SPMS patients and/or
CD4+ T cells and is consistent with SPMS as a non-
inflammatory mediated disease.
miR-155-5p and miR-142-3p have been identified as
dysregulated in RRMS PBMCs [22], and a recent study
on autologous hematopoietic stem cell transplant
(AHSCT) also found co-dysregulation of miR-155-5p
and miR-142-3p [23]. Contrary to our results, Arruda
et al. found these miRNAs to be up-regulated in MS pa-
tient CD4+ T cells before treatment (cohort was 75 %
SPMS). However, AHSCT is most effective in active MS
disease, and six of the 19 SPMS patients enrolled in the
Arruda et al. study presented with gadolinium-
enhancing lesions in the year approaching the treatment
indicating inflammatory activity. Further, the average
disease duration in the Arruda et al. study was 8.1 years,
as opposed to 25.6 (primary cohort) or 18.6 (replication
cohort) years in our study. Our data is corroborated fur-
ther by NGS expression analysis, which is a more sensi-
tive measure of expression changes.
In a study of potential biomarkers in Alzheimer’s
disease (AD), miR-26b-5p was shown to be down-
regulated in the serum and CSF of AD patients when
compared to patients with inflammatory neurological dis-
eases [24], supporting the predominantly neurodegenera-
tive pathology of SPMS. Over-expression of miR-29b
insystemic lupus erythematosus (SLE) has been linked
to hypomethylation of DNA in CD4+ T cells [25].
While there are currently no studies on DNA methyla-
tion in SPMS, it would be interesting to see if the
down-regulation of miR-29b that we have identified
here in CD4+ T cells is associated with genome-wide
hypermethylation in SPMS.
Increased miR-21-5p promotes differentiation of Th17
cells in the EAE mouse model, and miR-21-5p knock-
out mice are resistant to EAE [26]. Fenoglio et al. found
increased miR-21-5p expression in RRMS (active relapse
phase) PMBCs compared to controls, though no differ-
ence in SPMS. Again, this may be attributed to the rela-
tively small sample size (n = 6) [27].
Also of interest, we previously reported miR-20a-5p
down-regulation in the whole blood of all MS sub-
types [28]. This miRNA was one of the 42 dysregu-
lated miRNAs identified by NGS and is significantly
down-regulated in SPMS compared to HC. However,
it narrowly missed the 800 read cut-off for qPCR
confirmation. miR-20a-5p is also predicted to target
SOCS6.
Eight of the top ten dysregulated miRNAs were pre-
dicted to target SOCS6 using MirSystem. Consistent
with this, increased expression of SOCS6 in the SPMS
cohort is in direct negative correlation with the miRNA
expression profiles, strongly indicating a mRNA:miRNA
Table 2 Correlation coefficients calculated from RT-qPCR data against patient characteristics
miR-21-5p miR-26b-5p miR-29b-3p miR-142-3p miR-155-5p
EDSS 0.34 0.42 0.41 0.28 0.26
Age (HC) 0.22 0.17 0.31 0.21 −0.08
Age (SPMS) −0.07 −0.17 −0.17 −0.30 −0.01
Disease duration 0.49 0.15 0.23 −0.08 0.49
Progression duration 0.12 0.12 0.11 −0.07 0.17
Table 3 Genes identified by miRSystem targeted by eight of the ten microRNAs
miR-21-5p miR-23a-3p miR-26b-5p miR-27a-3p miR-27b-3p miR-29b-3p miR-30e-5p miR-142-3p miR-155-5p miR-221-3p
ACVR2B V V V V V V V V
ZBTB41 V V V V V V V V
BRWD1 V V V V V V V V
CAMTA1 V V V V V V V V
CFL2 V V V V V V V V
SOCS6 V V V V V V V V
MIER3 V V V V V V V V
KLF12 V V V V V V V V
Verified targeting miRNAs are identified with a “V”
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relationship. To our knowledge, this is the first study to
identify SOCS6 as a gene of interest in MS. It is a highly
conserved gene with very low expression levels in
healthy thymus and brain tissues and is down-regulated
in gastric, colorectal, and pancreatic cancers [29–32]. In
colorectal cancer, methylation changes have been ruled
out as the mechanism of down-regulation [31]; there-
fore, down-regulation may be due to altered miRNA
expression. MiR-424-5p is responsible for the down-
regulation of SOCS6 in pancreatic cancer [32]; however,
we found no differences in miR-424-5p expression be-
tween SPMS and HC in this study.
The function of SOCS6 as a negative regulator of T
cell activation [15] and its observed over-expression in
SPMS CD4+ T cells supports the notion of reduced im-
mune activity in SPMS. Very little is known about
SOCS6, and more studies are required to determine if it
may be a novel therapeutic target.
This is the first study to use NGS miRNA profiling to
assess miRNA expression in the CD4+ T cells of SPMS
patients. Future studies should focus on using the same
technique in treatment naïve RRMS patients to deter-
mine if this is a SPMS exclusive trend and remove the
confounding factor of treatment effects. Furthermore,
miRNA expression profiles of other cell subtypes should
be investigated, as whole blood analysis is likely masking
significant changes in individual cell subsets. Ideally, all
of our patients would have had inactive SPMS; however,
as SPMS is a difficult disease stage to define and collect,
we have included some active SPMS patients in this study.
In this study, we chose to focus on CD4+ T cells as they
are thought to be the main cell infiltrates. Our previous
studies also show that CD4+ T cells exhibit significant
changes in methylation profiles in RRMS [33, 34].
Conclusions
Here, we have shown a general down-regulation of miR-
NAs in CD4+ T cells compared to HC, with five miR-
NAs confirmed as significant in two independent assays.
This indicates that miRNA expression may be over-
normalizing in SPMS CD4+ T cells. SOCS6 is a pre-
dicted target of the majority of these miRNAs and, con-
sistent with this, we found SOCS6 to be up-regulated in
this cohort. These are novel findings that point towards
a diminished role for CD4+ T cells in SPMS and add fur-
ther evidence for SPMS being a neurodegenerative dis-
ease stage, not an inflammation-driven one.
Additional file
Additional file 1: Figure S1. Volcano plot of differentially expressed
miRNAs identified with NGS. The FDR-corrected significance threshold is
demarked with a green line at p < 1.2 × 10−4. Three miRNAs were identified
at the threshold. Mean read counts were low in all three miRNAs: miR-451a
(SPMS mean = 76.3, HC mean = 18.9), miR-1246 (SPMS mean = 94.9, HC
mean = 51.9), and miR-144-5p (SPMS mean = 15.1, HC mean = 5.5).
Differential expression could not be replicated with RT-qPCR. (PNG 57 kb)
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